ReviewOncoTargets and therapy2019
Selecting treatment options in refractory metastatic colorectal cancer.
Review in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.Journal of cancer research and clinical oncology · 2019Pooled it
- Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study.Advances in therapy · 2025Article
- CEBPB-mediated upregulation of SERPINA1 promotes colorectal cancer progression by enhancing STAT3 signaling.Cell death discovery · 2024Article
- Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.BMC cancer · 2024Article
- Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion.Frontiers in oncology · 2024Review
- MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer.Cell death & disease · 2022Article
- Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer.Frontiers in oncology · 2022Review
- Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.Military Medical Research · 2021Article
- Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial.International journal of clinical oncology · 2021Article
- Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer.Current treatment options in oncology · 2021Review
- RUNX1 regulates the proliferation and chemoresistance of colorectal cancer through the Hedgehog signaling pathway.Journal of Cancer · 2021Article
- Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.Journal of oncology · 2021Article
- Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.Molecular and clinical oncology · 2020Article
- Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall Survival.The AAPS journal · 2020Article
- Long Non-Coding RNA Cancer Susceptibility 9 (CASC9) Up-Regulates the Expression of ERBB2 by Inhibiting miR-193a-5p in Colorectal Cancer.Cancer management and research · 2020Article
- Circulating tumor DNA applications in monitoring the treatment of metastatic colorectal cancer patients.Gastroenterology and hepatology from bed to bench · 2019Review
- LINC00491 as a new molecular marker can promote the proliferation, migration and invasion of colon adenocarcinoma cells.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survival of patients with metastatic colorectal cancer (mCRC) has significantly improved in the last decade. Survival gains are not driven by advances in first-line therapy but by incremental additional effects of subsequent treatment lines. To maximize outcomes, patients should receive all active agents. Identification of patient subgroups is increasing individualization of treatment. Novel oral agents, such as regorafenib and TAS-102, as well as promising immunotherapeutic agents have offered salvage treatment options for refractory mCRC. Although most therapeutic developments for mCRC in the chemorefractory setting focuses on new targets and/or more potent agents, reconsideration of established targets has gained importance with the growth of a rational pharmacogenomic approach to drug development, such as HER2. The authors describe treatment options for patients with refractory colon cancer following first- and second-line therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.